NTBLQ (Notable Labs) Short-Term Debt: $0.00 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Notable Labs Short-Term Debt?

Notable Labs NTBLQ -90.00% Short-Term Debt is $0.00 Mil as of Jun. 2024.

Notable Labs's Short-Term Debt for the quarter that ended in Jun. 2024 was $0.00 Mil.

Notable Labs Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Notable Labs Short-Term Debt Related Terms

Notable Labs Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Notable Labs's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Notable Labs Short-Term Debt Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Short-Term Debt
0.00 0.00 0.00

Notable Labs Quarterly Data
Dec21 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
Short-Term Debt Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Notable Labs (NTBLQ) has a Short-Term Debt of $0.00 Mil as of Jun. 2024.
Is Notable Labs' Short-Term Debt too high?
Notable Labs' current Short-Term Debt is $0.00 Mil.
How does Notable Labs' Short-Term Debt compare to VRTX and REGN?
Notable Labs' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Notable Labs's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Notable Labs stock overvalued right now?
Notable Labs (NTBLQ) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Notable Labs (NTBLQ), the current Short-Term Debt is $0.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Notable Labs Business Description

Address 320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.